Microba Life Sciences (ASX:MAP) Capex-to-Revenue : 0.53 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Microba Life Sciences Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Microba Life Sciences's Capital Expenditure for the six months ended in Dec. 2023 was A$-1.72 Mil. Its Revenue for the six months ended in Dec. 2023 was A$3.27 Mil.

Hence, Microba Life Sciences's Capex-to-Revenue for the six months ended in Dec. 2023 was 0.53.

Microba Life Sciences Capex-to-Revenue Historical Data

The historical data trend for Microba Life Sciences's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Microba Life Sciences Capex-to-Revenue Chart

Microba Life Sciences Annual Data

Trend

Jun22

Jun23

Capex-to-Revenue

0.40

0.56

Microba Life Sciences Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Capex-to-Revenue	-	-	0.70	0.47	0.53

Competitive Comparison of Microba Life Sciences's Capex-to-Revenue

For the Diagnostics & Research subindustry, Microba Life Sciences's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Microba Life Sciences's Capex-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Microba Life Sciences's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Microba Life Sciences's Capex-to-Revenue falls into.

Microba Life Sciences Capex-to-Revenue Calculation

Microba Life Sciences's Capex-to-Revenue for the fiscal year that ended in Jun. 2023 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-3.037)	/	5.42
	=	0.56

Microba Life Sciences's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-1.719)	/	3.273
	=	0.53

Microba Life Sciences (ASX:MAP) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Microba Life Sciences Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Microba Life Sciences's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Microba Life Sciences (ASX:MAP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Microba Life Sciences Ltd (ASX:MAP) » Definitions » Capex-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

324 Queen Street, Level 10, Brisbane, QLD, AUS, 4000

Website

https://www.microba.com

Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome which includes delivering gut microbiome testing services globally to consumers, clinicians, and researchers. The company's segment includes Testing Services, and Research and Development.

Microba Life Sciences (ASX:MAP) Headlines

No Headlines